Company intelligence
SAX
About SAX
SAX is a multi-disciplinary accounting, tax and advisory firm serving the needs of privately held companies, family-owned businesses, not-for-profit organizations and high-net-worth individuals. For more than 65 years, we have offered industry-specific expertise, comprehensive service offerings and client-centric results. “SAX” is the brand name under which SAX LLP and SAX Advisory Group LLC and its subsidiary entities provide professional services. Our advisors are passionate, forward-thinking entrepreneurs who are driven to see their clients succeed. Through our unique Client Service Delivery Model, we offer the right business solutions to help our clients turn their dreams and vision into reality. With offices in Parsippany, N.J., Ewing, N.J. Morganville, NJ and New York City, we have a keen sense of what it takes to succeed in this competitive and ever-changing marketplace. Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Sax Capital Advisors is not a registered broker-dealer, and Finalis Securities LLC and Sax Capital Advisors are separate, unaffiliated entities.
Verified activity
Signals from SAX
5 published signals
Presence & Recognition
SAX hosted a Sneaker Drive at the Embassy Suites in Saratoga for networking and sneakers, collecting more than 50 pairs of sneakers and accepting donations through the end of next week.
Reported by Charles Amodio, CPA, CFF, MAFF, MBA
Presence & Recognition
SAX hosted an event hosted by the ACBA Young Lawyers Committee.
Reported by Charles Amodio, CPA, CFF, MAFF, MBA
Legal & Regulatory
SAX notes that testing requirements do not automatically change when rescheduling occurs, as they remain governed by state law and federal legal status remains unresolved.
Reported by Stacey Udell
Legal & Regulatory
SAX notes that state medical programs remain in charge of production rules, licensing, seed-to-sale tracking, facility requirements, batch testing, labeling, and dispensary rules, unless the state changes them.
Reported by Stacey Udell
Legal & Regulatory
SAX notes that rescheduling does not turn dispensary products into FDA-approved drugs, as they remain governed by state adult-use rules and federal legality remains unresolved.
Reported by Stacey Udell